중간위험도 전립선암의 치료
The Treatments for Intermediate Risk Prostate Cancer
심명선, 권택민, 김성철, 김완석, 추민수, 여정균,
소속 상세정보
심명선 ( Shim Myung-Sun )
한림대학교 의과대학 한림대학교성심병원 비뇨의학과
권택민 ( Kwon Taek-Min )
울산대학교 의과대학 울산대학교병원 비뇨기과
김성철 ( Kim Seong-Cheol )
인제대학교 의과대학 해운대백병원 비뇨기과
김완석 ( Kim Wan-Suk )
인제대학교 의과대학 인제대학교부산백병원 비뇨의학과
추민수 ( Choo Min-Soo )
한림대학교 의과대학 한림대학교동탄성심병원 비뇨의학과
여정균 ( Yeo Jeong-Kyun )
인제대학교 의과대학 인제대학교서울백병원 비뇨의학과
Abstract
The population of intermediate-risk prostate cancer patients is a large heterogeneous group with diverse prognoses and challenges the struggle to develop more meticulous and standardized treatment recommendations. Furthermore, there are no specific treatment guidelines based on Korean patients although the cancer nature of this patient group is known to be somewhat different from those of western patients. This review will examine the treatment options for intermediate-risk prostate cancer patients in specific clinical situations. The literature provides evidence that combining androgen deprivation therapy (ADT) for 6 months with radiation therapy (RT) may have superior survival than RT alone. Also, patients with adverse pathologic features and lymph node metastasis will benefit from adjuvant RT and ADT respectively after radical prostatectomy (RP). In addition, patients with life expectancy ≥10 years will benefit from lymphadenectomy during RP when lymph node metastasis is suspected as well as neurovascular bundle saving during RP is recommended because of its superior functional results.
키워드
Prostatic neoplasms; Prostatectomy;Radiotherapy;Antineoplastic agents
원문 및 링크아웃 정보
등재저널 정보